Annovis Bio Says Strong Enrollment in Study of Buntanetap for Parkinson’s Disease May Enable Q2 Interim Analysis – Marketscreener.com

Annovis Bio Says Strong Enrollment in Study of Buntanetap for Parkinson’s Disease May Enable Q2 Interim Analysis – Marketscreener.com
Source: Google NewsPublished on 2023-01-25